LTK Activators
LTK Activators refers to chemicals that can directly or indirectly lead to the activation of Leukocyte Receptor Tyrosine Kinase (LTK). These activators function primarily by modulating the signaling pathways that LTK is involved in. For example, inhibitors of protein kinases such as Staurosporine, and multi-targeted kinase inhibitors like Sorafenib and Dasatinib, can modulate the signaling pathways and thus indirectly activate LTK.
Compounds that can bind to specific receptors and lead to the activation of downstream signaling pathways can also act as indirect activators of LTK. For instance, Epidermal Growth Factor (EGF), Insulin, and Platelet-Derived Growth Factor (PDGF) can bind to their respective receptors, leading to the activation of PI3K/Akt and MAPK pathways. These pathways can then indirectly lead to the activation of LTK. Furthermore, compounds that inhibit specific components of these signaling pathways, such as the PI3K inhibitors LY294002 and Wortmannin, and the MEK inhibitors U0126 and PD98059, can also modulate the activation of LTK. Finally, Forskolin, a direct activator of adenylyl cyclase, can increase cAMP levels, activating Protein Kinase A (PKA), which can then phosphorylate and activate LTK. All these chemicals exemplify the complex and diverse ways in which the activation of LTK can be modulated.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, broad-spectrum inhibitor of protein kinases, including LTK. By inhibiting LTK, it can modulate its downstream signaling, and thus indirectly activate it. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is a direct activator of adenylyl cyclase, resulting in increased cAMP levels. cAMP can activate Protein Kinase A (PKA), which can phosphorylate and activate LTK. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin can bind to its receptor and activate the PI3K/Akt pathway, which can indirectly lead to the activation of LTK. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that can inhibit multiple kinases, including FLT3, VEGFR, and PDGFR. By inhibiting these kinases, it can modulate the signaling pathways that LTK is involved in, thus indirectly activating it. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-targeted kinase inhibitor that can inhibit Src family kinases. By inhibiting Src kinases, it can modulate the signaling pathways that LTK is involved in, thus indirectly activating it. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, it can modulate the PI3K/Akt pathway, leading to indirect activation of LTK. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can modulate the PI3K/Akt pathway, leading to the indirect activation of LTK. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent, irreversible inhibitor of PI3K. By inhibiting PI3K, it can modulate the PI3K/Akt pathway, leading to indirect activation of LTK. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK1, which can modulate the MAPK pathway, leading to indirect activation of LTK. | ||||||